Adverum Biotechnologies, Inc. (ADVM)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Adverum Biotechnologies, Inc. (ADVM)
Go deeper and ask any question about ADVM
Company Performance
Current Price
as of Sep 13, 2024$7.23
P/E Ratio
N/A
Market Cap
$150.39M
Description
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Metrics
Overview
- HQRedwood City, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerADVM
- Price$7.23+2.55%
Trading Information
- Market Cap$150.39M
- Float67.82%
- Average Daily Volume (1m)155,256
- Average Daily Volume (3m)325,537
- EPS-$7.99
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$18.48M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$28.13M
- EV$43.11M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account
Factset